Jazz Pharmaceuticals Deal History & Licensing Activity
Jazz Pharmaceuticals is a large biotech headquartered in Ireland. Over the past three years, Jazz Pharmaceuticals has been involved in 5 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (6 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
4
Active Trials
50
Top Modality
Bispecific Antibodies
Focus Area
Solid Tumors
Jazz Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Jazz Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| T cell engagers program | AbCellera Biologics | Bispecific Antibodies | Unknown | collaboration | Jul 12, 2026 |
| T cell engager discovery and development program | AbCellera | Bispecific Antibodies | Discovery | collaboration | Jun 23, 2026 |
| T-cell engaging multispecific antibodies program | AbCellera | Bispecific Antibodies |
Jazz Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Jazz Pharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Jazz Pharmaceuticals Strategic Signals
Key indicators of Jazz Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Jazz Pharmaceuticals Clinical Pipeline
Jazz Pharmaceuticals has 50 active clinical trials across 5 development phases.
3
Phase 4
4
Unknown
19
Phase 1
17
Phase 2
7
Phase 3
See How Your Asset Matches Jazz Pharmaceuticals's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Jazz Pharmaceuticals Licensing & Deal Activity
Jazz Pharmaceuticals is a large biotech company based in Ireland that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Jazz Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Jazz Pharmaceuticals include Solid Tumors (20 deals and trials), CNS Disorders (8 deals and trials), Hematological Malignancies (7 deals and trials), and Mega Deals (2 deals and trials). In terms of modality, Jazz Pharmaceuticals has shown particular interest in bispecific antibodies, small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Jazz Pharmaceuticals and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Jazz Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.